Skip to content
Health Policy Strategies

When Washington acts, know what it means for your business.

Health Policy Strategies analyzes how Medicare and Medicaid coverage, payment, and reimbursement policy affects the commercial success of biopharmaceutical, device, and diagnostic companies.

Federal Register / Vol. 91, No. 135Thursday, July 16, 202643843

Centers for Medicare & Medicaid Services

CY 2027 Physician Fee Schedule

Proposed rule, CMS-1848-P

I. Executive Summary

A. Purpose

… 340B covered entities to submit Part D 340B claims data …

Source: 91 FR 43843

What we do

Every example here comes from a recent CMS rule.

  • CY 2026 Physician Fee Schedule, final rule

    • FinalizedEfficiency adjustment of 2.5% to work RVUs for most non-time-based services
    • FinalizedManufacturers must document the fair market value method for bona fide service fees
    • NOT FINALIZEDThe two proposed fair market value methods for bona fide service fees
    Source: CMS, CY 2026 PFS final rule

    Rule analysis and briefings

    We read each relevant CMS proposed and final rule in full. You get a clear summary and its business impact: what CMS proposed, what it finalized, and what it did not finalize, with citations and effective dates.

  • Skin substitutes: how Medicare Part B pays

    2025As biologicals, based on ASP
    2026Non-351 products: incident-to supplies, one rate per sq cm
    2027Proposed: non-sheet forms priced nationally, per sq cm of wound
    Source: CMS, CY 2026 PFS final rule; CY 2027 PFS proposed rule

    Coverage, coding, and payment strategy

    We advise on how Medicare and Medicaid coverage, coding, payment, and reimbursement policy affects your products, from pre-launch planning through lifecycle management.

  • On our watch list

    1. CY 2027 PFS proposed rule published, 91 FR 43842
    2. Comments due on the CY 2027 PFS proposed rule
    3. Medicare Part D 340B repository opens for voluntary data
    4. First quarterly deadline for 340B repository data
    Source: Federal Register; CMS Part D 340B repository fact sheet

    Policy monitoring

    We track CMS, the Federal Register, and other federal agencies daily, and send a weekly briefing on the developments that matter to your portfolio.

  • Physician fee schedule conversion factor

    $34.89$32.84 proposed20212027
    Source: CMS rules. 2024: rate from March 9. 2026 and 2027: non-qualifying APM rate

    Multi-year trend analysis

    We analyze how payment rules and their impact change across years, so your team can plan for where policy is going, not only where it is.

Who we advise

Biopharmaceutical companies and device and diagnostic manufacturers whose products depend on Medicare and Medicaid coverage and payment.

Many of our client relationships have lasted more than a decade.

What we watch for you

  • Biopharmaceutical

    • Medicare Part B drug payment and ASP
    • Medicare Part D
    • Medicare inflation rebates
    • 340B and Medicaid drug rebates
    • HCPCS coding
  • Medical device

    • Medicare coverage, including TCET
    • Hospital outpatient and ASC payment
    • Physician fee schedule
  • Diagnostics

    • Clinical Laboratory Fee Schedule
    • National and local coverage decisions
    • Test coding
    • Physician fee schedule

Teams we work with: Market access, Government affairs and policy, Pricing and reimbursement, Commercial leadership.

How we work

One real rule, start to finish: CY 2027 Physician Fee Schedule proposed rule

  1. Monitor

    We watch CMS, the Federal Register, FDA, and Congress for actions that touch your products.

    CMS posts the rule for public inspection.

  2. Analyze

    We read the full text and isolate the provisions that affect your portfolio.

    We read the full rule and pull out the drug and biotech provisions.

  3. Brief

    You get a client-ready summary with direct quotes, citations, and dates.

    Clients get a summary deck.

  4. Advise

    We walk your team through the impact and the options, one call at a time.

    We walk each client through the impact before comments are due.

Why clients stay

  • Senior advice on every call.

    Every analysis and every call comes from a senior advisor, not a rotating team.

  • Policy, law, and public health together.

    We bring training in health law and public health, and experience inside BIO and at two Washington law firms.

  • Precision you can act on.

    Summaries cite the rule, the section, and the effective date. You know what changed and when.

Insights and media

Conversations on drug pricing, FDA policy, and Medicare Part D.

AVBCC Value-Based Voices

The Association for Value-Based Cancer Care podcast on the policies that shape access to cancer care. Hosted by Jayson Slotnik of Health Policy Strategies.

Leadership

Jayson Slotnik

Jayson Slotnik, JD, MPH

Founding Partner, Health Policy Strategies

Jayson counsels biotech, pharmaceutical, device, and diagnostic companies on how Medicare and Medicaid coverage, payment, reimbursement, coding, and broader government policy affect commercial success.

Background

  • First Director, Medicare Reimbursement and Economic PolicyBiotechnology Industry Organization (BIO)
  • Health law practiceTwo Washington, D.C. law firms
  • Vice President, Reimbursement and Innovation StrategiesUnited BioSource Corporation
  • Board memberAssociation for Value-Based Cancer Care
  • Podcast hostAVBCC Value-Based Voices
  • Editorial boardsValue-Based Cancer Care; Specialty Pharmacy Times
  • Washington Insights columnistSpecialty Pharmacy Times

Education

  • JD, Health Law, University of Maryland School of Law
  • MPH, Epidemiology and Biostatistics, The George Washington University
  • BA, English, University of Rochester
LinkedIn

Get the weekly policy brief

A short weekly email on the CMS, FDA, and congressional developments worth your attention.

One email a week. Unsubscribe any time.

We’ll never sell your information.

Get in touch

Tell us about your product and the policy question in front of you. A senior advisor reads every message.

We’ll never sell your information.